Learn about emerging treatments for metastatic liver cancer. We’ve got it covered, from new FDA approvals to emerging approaches in targeted therapy, immunotherapy, ablation, surgery, modified viruses, and more.

  • October 16, 2020 

    Hepatocellular Carcinoma (HCC)—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)

    .

  • August 7, 2020 

    FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark

    George Lundberg, MD

    Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

    Go to full article published by GenomeWeb.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 26, 2019 

    Radiofrequency Ablation (RFA) of Liver TumorsBookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Although generally not well recognized in the U.S., radiofrequency ablation (RFA) therapy can be highly effective in managing localized smaller lever cancers. Learn more about this treatment approach from the University of Pittsburgh Medical Center.

    .

  • August 17, 2019 

    Primary Hepatic CarcinomaBookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Primary liver cell cancer is one of the most common causes of cancer deaths throughout the world. Usually arising in cirrhotic livers, its treatment modalities are many and varied. Cures are elusive except for liver transplantation, but many therapy modalities can sustain prolonged survival. This overview from Medscape provides useful information about the disease.

    .

    • Show More
What if your doctor could know what everyone collectively knew?

Marty Tenenbaum, PhD
Founder of Cancer Commons

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in molecular testing that could help guide liver cancer treatment, such as detection of genetic mutations and other biomarkers.

Some of the most promising new treatments for metastatic liver cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • October 8, 2020 

    Innovent Biologics’s TYVYT/Byvasda combo shows survival benefit in late-stage liver cancer studyBookmark

    George Lundberg, MD

    Article from Seeking Alpha curated by Contributing Editor George Lundberg, MD, who notes: 

    In a phase 3 clinical trial, a new drug combination improved both overall survival and progression-free survival for people with hepatocellular carcinoma.

    .

  • May 30, 2020 

    Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular CarcinomaBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a combination of the drugs atezolizumab and bevacizumab improved both progression-free survival and overall survival in advanced hepatocarcinoma (the most common form of liver cancer), with fewer adverse effects. These findings were reported in the New England Journal of Medicine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular CarcinomaBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More
It has been extremely gratifying to see how Cancer Commons has brought clarity and greater access to this expertise through its convening and curation.

Keith Flaherty, MD
Cancer Commons Advisor

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories.

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.